Allergan's Abicipar Effective With Fewer Injections, But More Inflammation In AMD
Allergan and Molecular Partners said dosing of the VEGF inhibitor every eight or 12 weeks was non-inferior to Lucentis every four weeks. But while AMD patients would enjoy fewer sharp pokes in the eye, about 15% may experience inflammation – at least until a new formulation is available.
You may also be interested in...
With a complete response letter for wet AMD drug abicipar, AbbVie is expected to move on from the drug acquired with Allergan. Molecular Partners now seems inclined to focus on IO, virology.
The latest drug development news and highlights from our US FDA Performance Tracker.
Allergan has been developing abicipar to provide less-frequent dosing in neovascular AMD, but despite success in reducing intraocular inflammation with a new formulation, the injectable still doesn’t match the safety of entrenched competitors.